LiverAce COMBO Kit
Hepatotoxicity / Drug-Induced Liver Injury (DILI)
RUO (Projected regulatory clearance 2027)Active
Key Facts
Indication
Hepatotoxicity / Drug-Induced Liver Injury (DILI)
Phase
RUO (Projected regulatory clearance 2027)
Status
Active
Company
About DestiNA Genomics
DestiNA Genomics has developed a proprietary, platform-agnostic chemistry (DGL-Tech/ChemiRNA Tech) that transforms standard immunoassay workflows into tools for direct, extraction-free miRNA and protein detection. This approach aims to unlock the use of miRNA biomarkers in drug development and diagnostics by providing more stable, accurate, and comprehensive data, including full isomiR profiles. The company is currently commercializing Research Use Only (RUO) kits for hepatotoxicity testing and is seeking licensing partners to expand the application of its core technology.
View full company profileTherapeutic Areas
Other Hepatotoxicity / Drug-Induced Liver Injury (DILI) Drugs
| Drug | Company | Phase |
|---|---|---|
| LiverAce SinglePlex Kit | DestiNA Genomics | RUO |